| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 80,373 |
| Change in provision for bad debts | 5,423 |
| Prepaid expenses, other current assets and deposits | -417,738 |
| Inventories | -94,002 |
| Accounts receivable | -33,782 |
| Accounts payable and accrued liabilities | -172,657 |
| Net loss from continuing operations | -9,585,822 |
| Depreciation and amortization | 255,601 |
| Loss on write-off of property and equipment | 5,212 |
| Unrealized gain on change in fair value of warrants classified as a liability | 318,840 |
| Deferred revenue | 43,500 |
| Net cash used in operating activities from continuing operations | -9,141,688 |
| Purchase of property and equipment | 313,121 |
| Net cash used in investing activities from continuing operations | -313,121 |
| Net proceeds from exercise of warrants | 2,215,828 |
| Net proceeds from issuance of common stock and pre-funded warrants | 5,712,700 |
| Net cash provided by financing activities from continuing operations | 7,928,528 |
| Cash used in operating activities | -185,679 |
| Cash provided by investing activities | 21,000 |
| Net cash used by discontinued operations | -164,679 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -1,690,960 |
APPLIED DNA SCIENCES INC (APDN)
APPLIED DNA SCIENCES INC (APDN)